Form 4: NovoCure COO Sells Shares for Tax Obligations

NovoCure's Chief Operating Officer, Mukund Paravasthu, disposed of shares to cover tax withholding obligations related to Restricted Stock Unit vesting.

Summary

• Mukund Paravasthu, Chief Operating Officer of NovoCure Ltd., reported two transactions involving the disposal of ordinary shares.
• On November 1, 2025, 168 ordinary shares were disposed of at a price of $12.81 per share.
• On November 4, 2025, an additional 2,949 ordinary shares were disposed of at a price of $12.23 per share.
• These disposals represent shares withheld by the issuer to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs).
• The transactions were non-discretionary and approved pursuant to Rules 16b-3(e) and 16b-3(d)(1).
• Following these transactions, Mukund Paravasthu beneficially owns 80,439 ordinary shares directly.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary sale of shares by an officer to cover tax obligations related to RSU vesting. This is a neutral event and does not indicate a change in company fundamentals or management's outlook.

Future Outlook

This filing does not contain any forward-looking statements or guidance.

Management Comments

• The transactions represent the number of shares required to be withheld by the issuer to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.
• These transactions are not discretionary and approved as required pursuant to Rules 16b-3(e) and 16b-3(d)(1).

Industry Context

This is a routine insider transaction (Form 4) for tax withholding purposes, common across publicly traded companies when Restricted Stock Units (RSUs) vest for executives. It does not reflect broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in company performance or management's confidence.

Key Dates

Recommendation

The filing details a routine, non-discretionary sale of shares by a company officer to cover tax obligations related to Restricted Stock Unit vesting. This type of transaction is not indicative of management's view on the company's future performance and typically has no material impact on the stock's fundamental value or outlook, thus a 'hold' recommendation is appropriate as no new fundamental information is presented to alter an existing investment thesis.

Keywords

NovoCure, NVCR, Form 4, Insider Transaction, Share Sale, RSU, Tax Withholding, Mukund Paravasthu, Chief Operating Officer